Longitudinal Assessment of Illnesses, Stress Dosing, and Illness Sequelae in Patients With Congenital Adrenal Hyperplasia
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Context: Patients with congenital adrenal hyperplasia (CAH) are at risk for life-threatening adrenal crises. Management of illness episodes aims to prevent adrenal crises. Objective: We evaluated rates of illnesses and associated factors in patients with CAH followed prospectively and receiving repeated glucocorticoid stress dosing education. Methods: Longitudinal analysis of 156 patients with CAH followed at the National Institutes of Health Clinical Center over 23 years was performed. The rates of illnesses and stress-dose days, emergency room (ER) visits, hospitalizations, and adrenal crises were analyzed in relation to phenotype, age, sex, treatment, and hormonal evaluations. Results: A total of 2298 visits were evaluated. Patients were followed for 9.3 ± 6.0 years. During childhood, there were more illness episodes and stress dosing than adulthood (P < 0.001); however, more ER visits and hospitalizations occurred during adulthood (P ≤ 0.03). The most robust predictors of stress dosing were young age, low hydrocortisone and high fludrocortisone dose during childhood, and female sex during adulthood. Gastrointestinal and upper respiratory tract infections (URIs) were the two most common precipitating events for adrenal crises and hospitalizations across all ages. Adrenal crisis with probable hypoglycemia occurred in 11 pediatric patients (ages 1.1 to 11.3 years). Undetectable epinephrine was associated with ER visits during childhood (P = 0.03) and illness episodes during adulthood (P = 0.03). Conclusions: Repeated stress-related glucocorticoid dosing teaching is essential, but revised age-appropriate guidelines for the management of infectious illnesses are needed for patients with adrenal insufficiency that aim to reduce adrenal crises and prevent hypoglycemia, particularly in children.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, in a longitudinal study of patients across all ages with CAH, gastrointestinal and upper respiratory tract infections were the two most common precipitating events for adrenal crises and hospitalizations.47”
From Adrenal crisis: prevention and management in adult patients (2019) · cites this paper as [47]
In the citing paper
“Low dose glucocorticoid therapy is associated with increased episodes of illness57 and adrenal crises58, and premature mortality in CAH might be primarily due to adrenal crisis.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [58]
In the citing paper
“Infectious illnesses can trigger an adrenal crisis and gastrointestinal and upper respiratory tract infections are the most common precipitants at all ages57,58,62,71.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [58]
In the citing paper
“Aldosterone deficiency exacerbates adrenal crisis through sodium and water loss and potassium retention, and adrenomedullary dysfunction (adrenaline deficiency) contributes to the risk of cardiovascular instability and hypoglycaemia58,68.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [58]
In the citing paper
“Therefore, treating pediatricians are constantly faced with the risk of over- and under-dosing their patients, which may lead to complications of excess steroid therapy ( Falhammar et al., 2014 ) and adrenal crisis ( El-Maouche et al., 2018 ), respectively.”
From Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach (2023) · cites this paper as El-Maouche et al., 2018
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769 · cited 4×
“The Endocrine Society clinical practice guidelines for the management of CAH (4) and primary adrenal insufficiency (1) suggest judicious use of glucocorticoid in NC patients, and even mild cortisol impairment generally does not lead to Addisonian crisis (1, 17, 18).”
BackgroundSelf-citationSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationNational Health and Nutrition Examination Survey
(2008) · Encyclopedia of Epidemiology · doi:10.4135/9781412953948.n305 · Cited by 1,342
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 1×
“Similarly, increasedmortality inAddison disease has been attributed to adrenal crisis (8).”
BackgroundHahner, S., Spinnler, C., Fassnacht, M., Burger-Stritt, S., Lang, K., Milovanovic, D., Beuschlein, F., Willenberg, H. S., Quinkler, M., & Allolio, B. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3191 · Cited by 394
Hahner, S., Loeffler, M., Bleicken, B., Drechsler, C., Milovanovic, D., Fassnacht, M., Ventz, M., Quinkler, M., & Allolio, B. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0884 · Cited by 346
Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313 · cited 4×
“HC equivalency dose was calculated by multiplying prednisone dose by 5 or dexamethasone dose by 80 (11).”
MethodSelf-citationAdrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency.
Merke, D. P., Chrousos, G. P., Eisenhofer, G., Weise, M., Keil, M. F., Rogol, A. D., Van Wyk, J. J., & Bornstein, S. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431903 · Cited by 266 · cited 1×
“ylase deficiency (35), predisposes to hypoglycemia.”
Self-citationBidet, M., Bellanné-Chantelot, C., Galand-Portier, M.-B., Tardy, V., Billaud, L., Laborde, K., Coussieu, C., Morel, Y., Vaury, C., Golmard, J.-L., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1582 · Cited by 213 · cited 2×
“The Endocrine Society clinical practice guidelines for the management of CAH (4) and primary adrenal insufficiency (1) suggest judicious use of glucocorticoid in NC patients, and even mild cortisol impairment generally does not lead to Addisonian crisis (1, 17, 18).”
Background
Cited by
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationCongenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
Self-citationRushworth, R. L., Torpy, D. J., & Falhammar, H. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1807486 · Cited by 262
Hahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
Congenital adrenal hyperplasia
Auer, M. K., Nordenström, A., Lajic, S., & Reisch, N. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01330-7 · Cited by 215
Nordenström, A., & Falhammar, H. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0712 · Cited by 158
Adrenal crisis: prevention and management in adult patients
Dineen, R., Thompson, C. J., & Sherlock, M. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819848218 · Cited by 123
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Self-citationModified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
Merke, D. P., Mallappa, A., Arlt, W., Brac de la Perriere, A., Lindén Hirschberg, A., Juul, A., Newell-Price, J., Perry, C. G., Prete, A., Rees, D. A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab051 · Cited by 109
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundResultSelf-citationThe Impact of SARS-Cov-2 Virus Infection on the Endocrine System
Somasundaram, N. P., Ranathunga, I., Ratnasamy, V., Wijewickrama, P. S. A., Dissanayake, H. A., Yogendranathan, N., Gamage, K. K. K., de Silva, N. L., Sumanatilleke, M., Katulanda, P., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa082 · Cited by 94
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
Auchus, R. J., Hamidi, O., Pivonello, R., Bancos, I., Russo, G., Witchel, S. F., Isidori, A. M., Rodien, P., Srirangalingam, U., Kiefer, F. W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404656 · Cited by 79
“35,36 Fatigue, possibly due to withdrawal symptoms precipitated by GC reduction, was more common with crinecerfont but generally resolved without treatment.”
Self-citationDisorders of Sex Development of Adrenal Origin
Finkielstain, G. P., Vieites, A., Bergadá, I., & Rey, R. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.770782 · Cited by 67
“Clinical features include ambiguous genitalia in both 46,XX and 46,XY fetuses and adrenal insufficiency of both glucocorticoids and mineralocorticoids (54).”
BackgroundPrimary adrenal insufficiency in childhood: data from a large nationwide cohort
Capalbo, D., Moracas, C., Cappa, M., Balsamo, A., Maghnie, M., Wasniewska, M. G., Greggio, N. A., Baronio, F., Bizzarri, C., Ferro, G., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa881 · Cited by 47
Adrenal crises in older patients
Rushworth, R. L., Torpy, D. J., & Falhammar, H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30122-4 · Cited by 48
Adrenal crises in children with adrenal insufficiency: epidemiology and risk factors
Eyal, O., Levin, Y., Oren, A., Zung, A., Rachmiel, M., Landau, Z., Schachter‐Davidov, A., Segev‐Becker, A., & Weintrob, N. (2019) · European Journal of Pediatrics · doi:10.1007/s00431-019-03348-1 · Cited by 47
Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia
Prete, A., Auchus, R. J., & Ross, R. J. (2022) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 46
Ali, S. R., Bryce, J., Haghpanahan, H., Lewsey, J. D., Tan, L. E., Atapattu, N., Birkebaek, N. H., Blankenstein, O., Neumann, U., Balsamo, A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa694 · Cited by 39
“This is contrary to the findings of others where these adverse events were more likely in girls (7, 34).”
BackgroundResultInfluentialChallenges in treatment of patients with non-classic congenital adrenal hyperplasia
Adriaansen, B. P. H., Schröder, M. A. M., Span, P. N., Sweep, F. C. G. J., van Herwaarden, A. E., & der Grinten, H. L. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1064024 · Cited by 51
“(22) reported Addisonian crises in NCCAH patients receiving hydrocortisone treatment.”
BackgroundThe management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum
Maher, J. Y., Gomez‐Lobo, V., & Merke, D. P. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09770-5 · Cited by 48
“It is important to review with the patient and family the requirements for higher doses of glucocorticoid during illnesses, similar to “sick day rules” in the nonpregnant state, [81] but which may include episodes of hyperemesis [49].”
BackgroundSelf-citationNeumann, U., Braune, K., Whitaker, M. J., Wiegand, S., Krude, H., Porter, J., Digweed, D., Voet, B., Ross, R. J. M., & Blankenstein, O. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa626 · Cited by 38
“crises in patients with CAH found that receiving lower hydrocortisone doses had associated higher rates of stress dosing and illnesses and were a risk factor for adrenal crises (19).”
BackgroundAli, S., Lucas-Herald, A. K., Bryce, J., & Ahmed, S. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184405 · Cited by 35
“Data on the frequency of adverse events in adrenal insufficiency have been collected in different settings such as local centres [33] as well as at a national level [34].”
BackgroundSarafoglou, K., Merke, D. P., Reisch, N., der Grinten, H. L. C., Falhammar, H., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad134 · Cited by 35
Self-citationClinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision)
Ishii, T., Kashimada, K., Amano, N., Takasawa, K., Nakamura‐Utsunomiya, A., Yatsuga, S., Mukai, T., Ida, S., Isobe, M., Fukushi, M., et al. (2022) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2022-0009 · Cited by 37
The Changing Epidemiology of Adrenal Insufficiency: Iatrogenic Factors Predominate
Rushworth, R. L., & Torpy, D. J. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad017 · Cited by 29
“cohort studies, with an increased incidence of ACs in treated AI [6, 16, 17].”
BackgroundLong‐term health consequences of congenital adrenal hyperplasia
Pofi, R., Ji, X., Krone, N. P., & Tomlinson, J. (2023) · Clinical Endocrinology · doi:10.1111/cen.14967 · Cited by 30
Congenital Adrenal Hyperplasia
Fraga, N. R., Minaeian, N., & Kim, M. S. (2024) · Pediatrics in Review · doi:10.1542/pir.2022-005617 · Cited by 31
Chrisp, G. L., Maguire, A. M., Quartararo, M., Falhammar, H., King, B. R., Munns, C. F., Torpy, D. J., Hameed, S., & Rushworth, R. L. (2018) · Clinical Endocrinology · doi:10.1111/cen.13826 · Cited by 22
“As most of these illnesses were viral respiratory tract infections, this is consistent with recommended practice (3,15,16,19, 27).”
ResultRussian clinical practice guidelines «congenital adrenal hyperplasia»
Mokrysheva, N. G., Mel'nichenko, G. A., Adamyan, L. V., Troshina, E. A., Молашенко, Н. В., Игоревна, С. А., Uvarova, E. V., Esayan, E. R. M., Andreeva, E. N., Ужегова, Ж. А., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12787 · Cited by 30
Insulin Resistance in Congenital Adrenal Hyperplasia is Compensated for by Reduced Insulin Clearance
de Oliveira, D. M., Tura, A., Vasques, A. C. J., Camilo, D. F., Lima, M. M. D. O., de Lemos‐Marini, S. H. V., Gonçalves, E. M., Guerra‐Júnior, G., & Geloneze, B. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab010 · Cited by 18
Adrenal crises in adolescents and young adults
Rushworth, R. L., Chrisp, G. L., Bownes, S., Torpy, D. J., & Falhammar, H. (2022) · Endocrine · doi:10.1007/s12020-022-03070-3 · Cited by 19
Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care
Balagamage, C., Arshad, A., Elhassan, Y., Said, W. B., Krone, R. E., Gleeson, H. K., & Idkowiak, J. (2023) · Clinical Endocrinology · doi:10.1111/cen.14992 · Cited by 19
“1,2,30 In a longitudinal analysis of 156 patients at a single centre over an average of 9 years, the incidence of adrenal crisis events in childhood and adolescence was 10.2/100 patient ‐ years, lower than in adults with 7.2/100 patient ‐ years, but sick day episodes were more often in children.”
InfluentialManagement of Infants with Congenital Adrenal Hyperplasia
Dabas, A., Vats, P., Sharma, R., Singh, P., Seth, A., Jain, V., Batra, P., Gupta, N., Kumar, R., Kabra, M., et al. (2020) · Indian Pediatrics · doi:10.1007/s13312-020-1735-8 · Cited by 18
Kolli, V., da Cunha, I. W., Kim, S., Iben, J., Mallappa, A., Li, T., Gaynor, A., Coon, S. L., Quezado, M., & Merke, D. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.730947 · Cited by 13
“Increased adrenal volume and adrenocortical hyperplasia are associated with the development of comorbidities such as hypogonadism, and metabolic risk factors in patients with CAH (31).”
BackgroundSelf-citationTschaidse, L., Wimmer, S., Nowotny, H. F., Auer, M. K., Lottspeich, C., Dubinski, I., Schiergens, K. A., Schmidt, H., Quinkler, M. O., & Reisch, N. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae023 · Cited by 14
Merke, D. P., Mallappa, A., Parker, M., Sukin, C., Kulkarni, S. E., Keil, M. F., Ryzin, C. V., Hill, S. C., Reynolds, J. C., Cutler, G. B., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae824 · Cited by 13
Self-citationLoli, P., Menotti, S., di Filippo, L., & Giustina, A. (2025) · Endocrine · doi:10.1007/s12020-025-04341-5 · Cited by 16
“It is however worthy to note that in NCCAH patients adrenal crisis has only been reported in the setting of iatrogenic tertiary hypothalamic – pituitary – adrenal axis suppression [48].”
Weber, J., Tanawattanacharoen, V. K., Seagroves, A., Liang, M. C., Koppin, C. M., Ross, H. M., Bachega, T. A. S. S., Geffner, M. E., Serrano-Gonzalez, M., Bhullar, G., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab600 · Cited by 11
Chrisp, G. L., Quartararo, M., Torpy, D. J., Falhammar, H., & Rushworth, R. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.986342 · Cited by 10
“Despite efforts directed at education and prevention, ACs continue to occur at an estimated rate of 6 to 8 ACs/100 patient years in treated AI (8, 9).”
BackgroundMichelet, R., Melin, J., Parra-Guillen, Z. P., Neumann, U., Whitaker, J. M., Stachanow, V., Huisinga, W., Porter, J. B., Blankenstein, O., Ross, R. J. M., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0231 · Cited by 12
Coope, H., Parviainen, L., Withe, M., Porter, J. B., & Ross, R. J. M. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1903871 · Cited by 9
“comes including seizures, learning difficulties, coma and death [26].”
BackgroundChrisp, G. L., Torpy, D. J., Maguire, A. M., Quartararo, M., Falhammar, H., King, B. R., Munns, C. F., Hameed, S., & Rushworth, R. L. (2020) · Clinical Endocrinology · doi:10.1111/cen.14196 · Cited by 7
Bancos, I., Kim, H., Cheng, H. K.-H., Rodríguez-Lee, M., Coope, H., Cicero, S., Goldsmith, H., Lin, V. H., & Jeha, G. S. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2450423 · Cited by 9
“A longitudinal study of 156 patients conducted by the National Institutes of Health (NIH) found adrenal crises to be occurring at an incidence of 7.55 per 100 patient-years (7.2 for children, 10.2 for adults) [37].”
InfluentialRees, A., Merke, D. P., Arlt, W., de la Perrière, A. B., Hirschberg, A. L., Juul, A., Newell-Price, J. D. C., Prete, A., Reisch, N., Stikkelbroeck, N. M. M. L., et al. (2024) · Endocrine Connections · doi:10.1530/ec-24-0150 · Cited by 12
“In the extension study on MRHC, the incidence of adrenal crisis was at the low end of that reported in the literature (26, 27).”
BackgroundSelf-citationKoren, I., Weintrob, N., Kebesch, R., Majdoub, H., Stein, N., Naor, S., & Segev‐Becker, A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad546 · Cited by 6
Sandberg, D. E., Gardner, M., & Lapham, Z. K. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae668 · Cited by 7
Michelet, R., Bindellini, D., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Johnson, T. N., Whitaker, M. J., Ross, R., & Kloft, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1090554 · Cited by 5
Adrenal hyperplasias in childhood: An update
Pitsava, G., & Stratakis, C. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.937793 · Cited by 6
“Subsequently, DHEA is converted to testosterone by 3bHSD1 and thus both 46,XX and 46,XY present with ambiguous genitalia at birth (81).”
BackgroundTseretopoulou, X., Ali, S., Bryce, J., Amin, N. L., Atapattu, N., Bachega, T. A. S. S., Baronio, F., Ortolano, R., Birkebæk, N., Bonfig, W., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae145 · Cited by 6
“Viral illnesses are a common contributory factor for SDE in children [21] and it is possible that an explanation for the observed decrease in SDEs was the reduced incidence and transmission of pediatric viral and bacterial illnesses because of the lock-down during the COVID-19 pandemic period…”
BackgroundRushworth, R. L., Falhammar, H., & Torpy, D. J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1252577 · Cited by 6
Ali, S., Bryce, J., Krone, N. P., der Grinten, H. L. C., & Ahmed, S. F. (2022) · Hormone Research in Paediatrics · doi:10.1159/000525075 · Cited by 5
Challenges in managing disorders of sex development associated with adrenal dysfunction
Finkielstain, G. P., & Rey, R. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256393 · Cited by 6
“Adrenal insufficiency Hyperkalemia, hyponatremia, hypovolemic shock Mineralocorticoid deficiency Neonatal screening, early treatment [36] Hyperpigmentation, fatigue, headache, nausea, abdominal pain, postural dizziness, low cardiac output, hypoglycemia Glucocorticoid deficiency Sick day rules.”
BackgroundWitchel, S. F., Miller, T., McCann, E., & Gupta, A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae728 · Cited by 4
“For stress dosing, each dose could be appropriately increased, or the calculated dose (triple or double) can be divided into 4 equal doses administered every 6 hours (12).”
The way toward adulthood for females with nonclassic congenital adrenal hyperplasia
Ntali, G., Charisis, S., Kylafi, C. F., Vogiatzi, E., & Michala, L. (2021) · Endocrine · doi:10.1007/s12020-021-02715-z · Cited by 4
“3% with NC2D1OH, 42% females) at NIH, only two patients with NC21OHD had emergency room visits and/or hospitalizations [106].”
BackgroundRushworth, R. L., Falhammar, H., & Torpy, D. J. (2024) · Clinical Endocrinology · doi:10.1111/cen.15166 · Cited by 3
“This may be exacerbated by the modern approach to glucocorticoid replacement that uses multiday doses of short acting hydrocortisone and may influence the risk of acute AI ‐ related illness in susceptible patients [5, 8].”
Hamidi, O., Auchus, R. J., Correa, R. R., Levine, A. C., Wierman, M. E., Hartzell, A. L., Lin, V. H., & Bancos, I. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag147 · Cited by 4
COVID-19 in an Infant with Congenital Adrenal Hyperplasia: A Case Report
Azouz, H. J., Gerrits, P., Surhigh, J. M., & Puthanpurayil, S. K. (2020) · Global Pediatric Health · doi:10.1177/2333794x20958933 · Cited by 2
Clinical practice guidelines "Congenital adrenal hyperplasia in children" with comments
Чугунов, І., Kopylova, I., Kolodkina, A. A., Kalinchenko, N. Y., Vorontsova, M. V., Bezlepkina, O. B., Peterkova, V. A., & Mokrysheva, N. G. (2026) · Problems of Endocrinology · doi:10.14341/probl13767 · Cited by 1
Stokland, A. M., Breivik, L., Dalen, I., Steintorsdottir, S. D., Kildal, S., Nermoen, I., Lima, K., Svendsen, M., Sævik, Å. B., Dębowska, A., et al. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70153 · Cited by 1
“We found that lower normal doses of corticosteroid did not increase risk consistent with reports on patients with CAH [26].”
Tseng, T., Seagroves, A., Tanawattanacharoen, V. K., Liang, M. C., Koppin, C. M., Keenan, M. F., Davidowitz, E., Nguyen, E., Chand, S., Geffner, M. E., et al. (2023) · Clinical Endocrinology · doi:10.1111/cen.14876 · Cited by 3
Course of COVID-19 infection in patients with congenital adrenal hyperplasia
Javaid, R., Sinaii, N., Kollender, S., Desai, J., Moon, A., & Merke, D. P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1348130 · Cited by 1
Self-citationTseng, T., Seagroves, A., Koppin, C. M., Keenan, M. F., Putterman, E., Nguyen, E., Chand, S., Geffner, M. E., Chang, T. P., & Kim, M. S. (2019) · medRxiv · doi:10.1101/19005462 · Cited by 1
“stress-dose requirement (8) and as a risk factor for hospitalizations in CAH (10).”
BackgroundUna visión general sobre la crisis suprarrenal en el paciente pediátrico
Segura, C. M., Segura, V. M., & Trabado, S. J. T. (2023) · Revista Medica Sinergia · doi:10.31434/rms.v8i1.940
COVID-19 pneumonia in a congenital adrenal hyperplasia; a case reportPreprint
Saeidinia, A. (2024) · Authorea · doi:10.22541/au.170667412.29359311/v1
Innovative Pharmacometric Approaches to Inform Drug Development and Clinical Use
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4503-4
Ergenlikte Cinsel Gelişim Bozuklukları
Ayrancı, Y. M. (2024) · doi:10.5152/6819
Cinsel Gelişim Bozukluklarında Cerrahi Zamanlama ve Tedavi
Söylet, Y., Sezer, A., & Hakalmaz, A. E. (2024) · doi:10.5152/6812
Cinsiyet Gelişim Bozukluklarında Erken Dönem Ruhsal Sorunlar
Çağlayan, R. H. B., & Cantürk, A. E. (2024) · doi:10.5152/6818
Cinsiyet Gelişim Bozukluklarında Aile
Çağlayan, R. H. B., & Aydın, A. (2024) · doi:10.5152/6816
Cinsiyet Gelişim Bozukluğunda Psikiyatrik Açıdan Etik ve Hukuk
Çağlayan, R. H. B., & Anac, E. G. (2024) · doi:10.5152/6821
Cinsiyet Gelişim Bozukluklarında Uzun Dönem İzlem
Turan, H. (2024) · doi:10.5152/6815
Büyükünal, S. N. C., Hakalmaz, A. E., & Sezer, A. (2024) · doi:10.5152/6801
Cinsiyet Gelişim Bozukluklarında Damgalanma Stresi
Tosun, C. (2024) · doi:10.5152/6820
İnsan Gonad ve Cinsel Kanal Gelişiminin Embriyolojisi
Tarçın, G., & Evliyaoğlu, O. (2024) · doi:10.5152/6802
46, XX Cinsiyet Gelişim Bozuklukları
Bayramoğlu, E. (2024) · doi:10.5152/6808
Hormonal Olmayan Cinsel Gelişim Bozuklukları
Hakalmaz, A. E., & Sezer, A. (2024) · doi:10.5152/6810
Cinsel Gelişim Bozukluklarında Görüntüleme
Ucar, A. K., & Kuruğoğlu, S. (2024) · doi:10.5152/6806
Cinsiyet Gelişim Bozukluklarinda Psikiyatrik Komorbiditeler
Çirkin, B. (2024) · doi:10.5152/6817
Sezer, A., Aydın, A., Çakır, A. D., Cantürk, A. E., Ucar, A. K., Özcabı, B., Çirkin, B., Tosun, C., Aydın, D. B., Anaç, E., et al. (2024) · doi:10.5152/6800
46, XY Cinsiyet Gelişim Bozuklukları
Aydın, D. B., & Evliyaoğlu, O. (2024) · doi:10.5152/6807
Cinsiyet Gelişim Bozukluklarının Sınıflandırılması
Özcabı, B. (2024) · doi:10.5152/6804 · Cited by 1
Cinsel Gelişim Bozukluklarında Tanı
Özcabı, B., & Çakır, A. D. (2024) · doi:10.5152/6805 · Cited by 1
Gonad Gelişimi ve Cinsel Gelişim Bozukluğunun Moleküler Düzeneğ
Çakır, A. D. (2024) · doi:10.5152/6803
Cinsiyet Gelişim Bozukluklarında Malformasyon Sendromları
Özer, Y., & Bayramoğlu, E. (2024) · doi:10.5152/6811
Hakalmaz, A. E., & Eliçevik, M. (2024) · doi:10.5152/6813
Praktisches Management des Adrenogenitalen Syndroms
Wörther, H. (2025) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-025-00269-3
Nokoff, N., Fechner, P. Y., Kim, M. S., Marshall, I. H., Merke, D. P., Sarafoglou, K., Hartzell, A. L., Lin, V. H., & Thornton, P. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag192
Self-citationFlokas, M. E., Kulkarni, S., Lee, P., Li, Y., Sukin, C., Kollender, S., & Merke, D. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1810137
“Adrenal crises have been reported as the leading cause of death in patients with CAH (3, 4), and are most often triggered by infectious illnesses, especially gastrointestinal illnesses (5, 6).”
Self-citationZheng, C., Zhao, L., & Chen, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1878903
The evolution of new approaches to the treatment of congenital adrenal hyperplasia
Merke, D. P., & Auchus, R. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag033
Self-citation
Metadata
- Authors
- El-Maouche, D., Hargreaves, C. J., Sinaii, N., Mallappa, A., Veeraraghavan, P., & Merke, D. P.
- Affiliations
- National Institutes of Health Clinical Center, Bethesda, Maryland
- National Institutes of Health (US)
- Corresponding author
- Merke, Deborah P
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-22
- Volume
- 103
- Issue
- 6
- Pages
- 2336-2345
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC6276663
- OpenAlex
- W2790504505
- Cited by
- 93
- References
- 36
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 32 · 2023: 11 · 2022: 10 · 2021: 10 · 2020: 10 · 2019: 5 · 2018: 3
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute for Health and Care Research
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- congenital adrenal hyperplasia, adrenal crisis, stress dosing, glucocorticoid therapy, adrenal insufficiency, illness episodes, upper respiratory tract infection, gastrointestinal infections, hypoglycemia, epinephrine, emergency department visits, hospitalization, pediatric patients, fludrocortisone, cortisol
- MeSH terms
- Adolescent, Adrenal Insufficiency, Adrenal Hyperplasia, Congenital, Adult, Aged, Child, Child, Preschool, Female, Fludrocortisone, Glucocorticoids, Humans, Hydrocortisone, Infant, Longitudinal Studies, Male, Middle Aged, Phenotype, Sex Factors, Disease Progression, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.